Balyasny Asset Management
NAMS icon

Balyasny Asset Management’s NewAmsterdam Pharma NAMS Stock Holding History

Balyasny Asset Management’s Portfolio NAMS Stock Details NAMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-21,283
Closed -$353K – 3090
2024
Q3 		$353K Buy
+21,283
New +$368K ﹤0.01% 2409

Other funds holding NAMS

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Balyasny Asset Management's NAMS Position: Q4 2024 in Review

Balyasny Asset Management sold out of NewAmsterdam Pharma (NAMS) in Q4 2024, closing a stake of 21,283 shares — an estimated $353K sold.

Balyasny Asset Management first reported a position in NAMS in Q3 2024 and held it in 1 quarter. The position peaked at $353K in Q3 2024. 130 funds tracked by Wall St. Rank hold NAMS as of Q4 2024.

  • Balyasny Asset Management reported no remaining NewAmsterdam Pharma position as of Q4 2024 after selling out during the quarter.
  • Balyasny Asset Management sold 21,283 NewAmsterdam Pharma shares in Q4 2024, an estimated $353K.
  • Balyasny Asset Management first reported a position in NewAmsterdam Pharma in Q3 2024 and held it in 1 quarter.
  • Balyasny Asset Management's NewAmsterdam Pharma position peaked at $353K in Q3 2024.
  • 130 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q4 2024.

Based on Balyasny Asset Management's 13F filing for Q4 2024, filed 14 Feb 2025.